{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:49:46Z","timestamp":1791272986547,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40263-025-01267-4","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:20:13Z","timestamp":1769581213000},"page":"565-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing\u2013Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Gianmarco","family":"Abbadessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Marastoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Bile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Zangh\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cellerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cerqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lagonigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Rispoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Malag\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Ganino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mancinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Comar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Merlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Montepietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Surcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lavorgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"3","key":"1267_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Giovannoni G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"4","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1474-4422(21)00043-3","volume":"20","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Li R. An immunological perspective on the treatment of multiple sclerosis. Lancet Neurol. 2021;20(4):297\u2013310. https:\/\/doi.org\/10.1016\/S1474-4422(21)00043-3.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1267_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001183","volume":"9","author":"WM Rowles","year":"2022","unstructured":"Rowles WM, Hsu WY, McPolin K, Li A, Merrill S, et al. Transitioning from S1P receptor modulators to B cell-depleting therapies in multiple sclerosis: clinical, radiographic, and laboratory data. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1183. https:\/\/doi.org\/10.1212\/NXI.0000000000001183.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"1267_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"issue":"20","key":"1267_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90(20):e1805. https:\/\/doi.org\/10.1212\/WNL.0000000000005516.","journal-title":"Neurology"},{"key":"1267_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814064","volume":"13","author":"JB Torres","year":"2022","unstructured":"Torres JB, Roodselaar J, Sealey M, Ziehn M, Bigaud M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022;13:814064. https:\/\/doi.org\/10.3389\/fimmu.2022.814064.","journal-title":"Front Immunol"},{"issue":"3","key":"1267_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.27143","volume":"97","author":"SG Meuth","year":"2025","unstructured":"Meuth SG, Wolff S, M\u00fcck A, Willison A, Kleinschnitz K, et al. Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab. Ann Neurol. 2025;97(3):583\u201395. https:\/\/doi.org\/10.1002\/ana.27143.","journal-title":"Ann Neurol"},{"issue":"2","key":"1267_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139(9):2395\u2013405. https:\/\/doi.org\/10.1093\/brain\/aww173.","journal-title":"Brain"},{"issue":"Pt 11","key":"1267_CR10","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(Pt 11):3287\u201398.","journal-title":"Brain"},{"issue":"11","key":"1267_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 2023;80(11):1232\u201345.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, et al. 2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):591\u20132. https:\/\/doi.org\/10.1016\/S1474-4422(21)00095-8.","journal-title":"Lancet Neurol"},{"key":"1267_CR13","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting E2A. ICH Harmonised Guideline. 1994 [cited 2025 Aug 12]. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf. Accessed 12 Aug 2025."},{"issue":"1","key":"1267_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1\u201321. https:\/\/doi.org\/10.1214\/09-STS313.","journal-title":"Stat Sci"},{"key":"1267_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107442","volume":"209","author":"A Moregola","year":"2024","unstructured":"Moregola A, Bonacina F, Vingiani GB, Frapolli R, Turrini R, et al. Profiling the impact of anti-human CD20 monoclonal antibodies on lymphocyte B cell subsets and their precursors in the bone marrow and in lymphoid tissues in an immunocompromised mouse engrafted with human cells. Pharmacol Res. 2024;209:107442. https:\/\/doi.org\/10.1016\/j.phrs.2024.107442.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1267_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11481-019-09872-z","volume":"14","author":"C Huck","year":"2019","unstructured":"Huck C, Leppert D, Wegert V, Schmid C, Dunn R, et al. Low-dose subcutaneous anti-CD20 treatment depletes disease-relevant B cell subsets and attenuates neuroinflammation. J Neuroinflamm. 2019;14(4):709\u201319. https:\/\/doi.org\/10.1007\/s11481-019-09872-z.","journal-title":"J Neuroinflamm"},{"key":"1267_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02437","volume":"10","author":"MA Migotto","year":"2019","unstructured":"Migotto MA, Mardon K, Orian J, Weckbecker G, Kneuer R, et al. Efficient distribution of a novel zirconium-89 labeled anti-CD20 antibody following subcutaneous and intravenous administration in control and experimental autoimmune encephalomyelitis-variant mice. Front Immunol. 2019;10:2437. https:\/\/doi.org\/10.3389\/fimmu.2019.02437.","journal-title":"Front Immunol"},{"issue":"4","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859\u201373. https:\/\/doi.org\/10.1007\/s13311-017-0565-4.","journal-title":"Neurotherapeutics"},{"issue":"5566","key":"1267_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.1070238","volume":"296","author":"S Mandala","year":"2002","unstructured":"Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346\u20139.","journal-title":"Science"},{"issue":"7","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790\u20134. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"issue":"10","key":"1267_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562\u201375. https:\/\/doi.org\/10.1177\/13524585221078825.","journal-title":"Mult Scler"},{"issue":"4","key":"1267_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231203816","volume":"9","author":"J Kramer","year":"2023","unstructured":"Kramer J, Linker R, Paling D, Czaplinski A, Hoffmann O, et al. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2023;9(4):20552173231203816. https:\/\/doi.org\/10.1177\/20552173231203816.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"16","key":"1267_CR24","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):e1546\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000012700.","journal-title":"Neurology"},{"issue":"3","key":"1267_CR25","doi-asserted-by":"publisher","first-page":"e2096","DOI":"10.1212\/WNL.0000000000209610","volume":"103","author":"MJ Williams","year":"2024","unstructured":"Williams MJ, Amezcua L, Cohan SL, Cohen JA, Delgado SR, et al. Efficacy of ofatumumab and teriflunomide in patients with relapsing MS from racial\/ethnic minority groups: ASCLEPIOS I\/II subgroup analyses. Neurology. 2024;103(3):e2096\u2013110. https:\/\/doi.org\/10.1212\/WNL.0000000000209610.","journal-title":"Neurology"},{"issue":"10","key":"1267_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","volume":"28","author":"SL Hauser","year":"2022","unstructured":"Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5\u2009years. Mult Scler. 2022;28(10):1576\u201390. https:\/\/doi.org\/10.1177\/13524585221079731.","journal-title":"Mult Scler"},{"key":"1267_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105888","volume":"91","author":"CM Hersh","year":"2024","unstructured":"Hersh CM, Gorritz M, Chen CC, Smith W, Forbes A, et al. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024;91:105888. https:\/\/doi.org\/10.1016\/j.msard.2024.105888.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"1267_CR28","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","volume":"271","author":"A Zangh\u00ec","year":"2024","unstructured":"Zangh\u00ec A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, et al. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. J Neurol. 2024;271(7):4495\u2013502. https:\/\/doi.org\/10.1007\/s00415-024-12360-x.","journal-title":"J Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01267-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:21:18Z","timestamp":1773483678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01267-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01267-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are available on reasonable request, subject to restrictions imposed by patient confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Ethics approval was granted by the Ethics Committee of the Azienda Ospedaliera Universitaria \u2018Luigi Vanvitelli\u2019 (reference no. 11222\/20), and subsequently the study was authorized by the Ethics Committee of all participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants included in the study gave written informed consent according to the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"GA: payment or honoraria for speaking and\/or support for meeting attendance and\/or travel from Roche, Novartis, Merck, and Janssen-Cilag. MF: reports grants from Roche SpA, Novartis Pharma, Sanofi Genzyme, Merck, Biogen, and Bristol Myers Squibb\/Celgene; served as a scientific consultant for Roche SpA and Novartis Pharma. SB: payment or honoraria for speaking and\/or support for meeting attendance and\/or travel from Roche, Novartis, Biogen, Merck-Serono, Alexion, Horizon, Janssen-Cilag, Bristol Myers Squibb, and Viatris. MI: received grants from NIH, NMSS, and DISM; received consultation fees from Roche, Genzyme, Merck, Biogen, and Novartis. MCe: received personal compensation from Novartis, Sanofi Genzyme, and Teva, and consulting fees from Zambon. LL: payment or honoraria for speaking and\/or support for meeting attendance and\/or travel from Roche, Novartis, Biogen, Merck-Serono, Alexion, Horizon, Janssen-Cilag, Bristol Myers Squibb, and Viatris. LM: reports speaking honoraria from Roche and Novartis. ET: reports economic support for congress speaking, travel, and meeting attendance from Amgen, Roche, Novartis Pharma, Sanofi Genzyme, Merck, Biogen, and Bristol\u00a0Myers Squibb; served as a scientific consultant for Alexion, Biogen, and Novartis Pharma. DF: has received travel grants and\/or honoraria for speaking\/advisory boards from Alexion, Binding Site, Biogen, Bristol\u00a0Myers Squibb, Merck, Novartis, Roche, and Sanofi\u00a0Genzyme.\u00a0SG: has\u00a0received an\u00a0unrestricted grant by Roche; received speaker fees, travel support and\/or served on advisory boards of Novartis, Amgen, Janssen, Sanofi Genzyme, and Juvise Pharmaceuticals. All other authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"GA and MF conceived and designed the study, curated data, performed formal analyses and visualization, and drafted the manuscript. SB contributed to study conception and design, provided methodological oversight, supervised the project, and critically revised the manuscript for important intellectual content. SB is the guarantor. DM, FB, ES, AZ, MCe, RC, LE, VT, SS, GR, MRi, EL, AMa, SG, MRp, MV, GSc, PR, AS, SMa, CG, LM, ALu, GL, FR, MCo, GM, MVa, SMo, AMr, MGP, ASu, ET, EC, AF, DF, RF, LL, ED, AG, PC, MCa, and MI acquired clinical data and\/or recruited participants, contributed to data curation and interpretation, and reviewed and edited the manuscript. All authors approved the final version and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}